|Mr. Charles A. Rowland Jr., CPA, MBA||Chief Exec. Officer, Pres and Director||43.31k||N/A||58|
|Mr. Michael R. Martin||Co-Founder and Chief Operating Officer||292.64k||N/A||N/A|
|Mr. Dennis Bourgeault C.A.||Chief Financial Officer and Sec.||272.46k||N/A||N/A|
|Mr. Neil Solomons M.D.||Chief Medical Officer||336.08k||N/A||N/A|
|Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)||VP of Clinical Affairs||258.12k||N/A||N/A|
Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada. The companys lead drug candidate is Voclosporin, a calcineurin inhibitor, which is in Phase IIb clinical trial for the treatment of lupus nephritis. It has a collaboration agreement with Paladin Labs Inc. to maintain the patent portfolio for Voclosporin in Canada, South Africa, and Israel; and development, distribution, and license agreement with 3SBio, Inc. for Voclosporin in China, Hong Kong, and Taiwan. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.